FEATURED COMPANIES

The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market.

The report, the Global Biosimilars Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key questions answered in this report:- What will the market size be in 2016/2018 and what will be the growth rate?- What are key market trends?- What is driving this market?- What are the challenges to market growth?- Who are the key vendors in this market space?- What are the market opportunities and threats faced by key vendors?- What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.
SHOW LESS
READ MORE >

FEATURED COMPANIES

Commenting on the report, an analyst from the team said: “The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. ”

According to the report, one of the main drivers in this market is the increasing number of patent expirations. A number of biopharmaceutical patents are due to expire in the near future or have already expired. This has helped propel the growth of vendors in the Global Biosimilars market. Some of the blockbuster drugs that are expected to lose patent expiry are Remicade, Humira, and Rituxan.

Further, the report states that one of the key challenges in the market is the risks related to drug failure. Vendors face a high level of risk due to the huge investments involved in the development stage and the possible failure of drugs when launched.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

PLEASE SELECT A FORMAT

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

EUR 3110USD 3,300GBP 2,186

1 - 5 USERS Electronic (PDF)

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

EUR 3769USD 4,000GBP 2,650

SITE LICENSE Electronic (PDF)

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

EUR 9424USD 10,000GBP 6,625

ENTERPRISEWIDE Electronic (PDF)

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.